CBLL Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -59.61% compared to Ceribell, Inc.'s net margin of 12.65%. Ceribell, Inc.'s return on equity of -36.45% beat Electromed, Inc.'s return on equity of 18.89%.

Ceribell, Inc. has a consensus price target of $24.71, signalling upside risk potential of 25.33%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 29.45%. Given that Electromed, Inc. has higher upside potential than Ceribell, Inc., analysts believe Electromed, Inc. is more attractive than Ceribell, Inc..

Ceribell, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Ceribell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ceribell, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Ceribell, Inc. quarterly revenues are $22.6M, which are larger than Electromed, Inc. quarterly revenues of $16.9M. Ceribell, Inc.'s net income of -$13.5M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Ceribell, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 29.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ceribell, Inc. is 8.62x versus 3.71x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of -59.61% compared to Ceribell, Inc.'s net margin of -36.3%. Ceribell, Inc.'s return on equity of -36.45% beat Myomo, Inc.'s return on equity of -68.35%.

Ceribell, Inc. has a consensus price target of $24.71, signalling upside risk potential of 25.33%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 380.77%. Given that Myomo, Inc. has higher upside potential than Ceribell, Inc., analysts believe Myomo, Inc. is more attractive than Ceribell, Inc..

Ceribell, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

Ceribell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ceribell, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

Ceribell, Inc. quarterly revenues are $22.6M, which are larger than Myomo, Inc. quarterly revenues of $10.1M. Ceribell, Inc.'s net income of -$13.5M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, Ceribell, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ceribell, Inc. is 8.62x versus 1.02x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -59.61% compared to Ceribell, Inc.'s net margin of -862.39%. Ceribell, Inc.'s return on equity of -36.45% beat VolitionRX Ltd.'s return on equity of --.

Ceribell, Inc. has a consensus price target of $24.71, signalling upside risk potential of 25.33%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.60 which suggests that it could grow by 767.53%. Given that VolitionRX Ltd. has higher upside potential than Ceribell, Inc., analysts believe VolitionRX Ltd. is more attractive than Ceribell, Inc..

Ceribell, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Ceribell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ceribell, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Ceribell, Inc. quarterly revenues are $22.6M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Ceribell, Inc.'s net income of -$13.5M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Ceribell, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ceribell, Inc. is 8.62x versus 20.54x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -59.61% compared to Ceribell, Inc.'s net margin of 3.93%. Ceribell, Inc.'s return on equity of -36.45% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Ceribell, Inc. has a consensus price target of $24.71, signalling upside risk potential of 25.33%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 143.51%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Ceribell, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Ceribell, Inc..

Ceribell, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Ceribell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ceribell, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Ceribell, Inc. quarterly revenues are $22.6M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Ceribell, Inc.'s net income of -$13.5M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Ceribell, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 60.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ceribell, Inc. is 8.62x versus 0.67x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.